CellSource Co.,Ltd. Logo

CellSource Co.,Ltd.

Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.

4880 | T

Overview

Corporate Details

ISIN(s):
JP3423580004
LEI:
Country:
Japan
Address:
渋谷区渋谷一丁目23番21号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CellSource Co., Ltd. is a biotechnology company specializing in regenerative medicine. The company's core operation involves providing contract processing and storage services for tissues and cells to medical institutions. Its key services include the extraction of adipose-derived stem cells and the preparation of platelet-rich plasma (PRP) from patient-derived samples. By offering these specialized processing services, CellSource enables partner medical facilities to provide advanced regenerative therapies. The company's operations are primarily centered on its regenerative medicine-related business, and it also engages in a consumer-focused business segment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-14 08:30
Board/Management Information
臨時報告書
Japanese 20.3 KB
2025-06-30 10:09
Share Issue/Capital Change
訂正臨時報告書
Japanese 30.7 KB
2025-06-12 08:36
Registration Form
確認書
Japanese 8.7 KB
2025-06-12 08:35
Interim Report
半期報告書-第10期(2024/11/01-2025/10/31)
Japanese 203.7 KB
2025-06-12 08:33
Share Issue/Capital Change
臨時報告書
Japanese 30.6 KB
2025-01-31 07:37
Governance Information
内部統制報告書-第9期(2023/11/01-2024/10/31)
Japanese 22.6 KB
2025-01-31 07:36
Registration Form
確認書
Japanese 8.7 KB
2025-01-31 07:35
Registration Form
有価証券報告書-第9期(2023/11/01-2024/10/31)
Japanese 1.0 MB
2025-01-31 07:32
Post-Annual General Meeting Information
臨時報告書
Japanese 24.9 KB
2024-10-31 07:06
Board/Management Information
臨時報告書
Japanese 19.3 KB
2024-06-13 08:07
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-06-13 08:05
Quarterly Report
四半期報告書-第9期第2四半期(2024/02/01-2024/04/30)
Japanese 212.9 KB
2024-03-11 07:04
Report Publication Announcement
確認書
Japanese 8.8 KB
2024-03-11 07:03
Quarterly Report
四半期報告書-第9期第1四半期(2023/11/01-2024/01/31)
Japanese 162.2 KB
2024-01-25 08:35
Governance Information
内部統制報告書-第8期(2022/11/01-2023/10/31)
Japanese 22.9 KB

Automate Your Workflow. Get a real-time feed of all CellSource Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CellSource Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CellSource Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

REGENXBIO Inc. Logo
Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
United States of America
RGNX
Rein Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.
United States of America
RNTX
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel
REKA
Relay Therapeutics, Inc. Logo
Developing precision medicines for oncology & genetic diseases by analyzing protein motion.
United States of America
RLAY
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia
REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden
RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America
REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America
RVPH
Revolution Medicines, Inc. Logo
A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
United States of America
RVMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.